Do you want to read an article? Please log in or register.
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
Type 1 Diabetes
COMMENTED
Related content
Type 1 DiabetesDiabetic Complications
Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis
Diabetes Care.
Hampp C, Swain RS, Horgan C, Dee E, Qiang Y, Dutcher SK, Petrone A, Chen Tilney R, Maro JC, Panozzo CA
doi: 10.2337/dc19-1481.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
JAMA Intern Med.
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC
doi: 10.1001/jamainternmed.
Type 1 DiabetesDiabetic Complications
SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA Protocol
Diabetes Obes Metab.
Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC,
Zinman B
doi: 10.1111/dom.13811.
COMMENTED
Type 2 Diabetes
Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors
doi: 10.1210/clinem/dgaa200.
Type 2 Diabetes
Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study
Diabetes Obes Metab.
Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T
doi: 10.1111/dom.14189.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis
JAMA.
Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K
doi: 10.1001/jama.2018.3024.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
BMJ
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM
doi: 10.1136/bmj.m4573
Type 2 DiabetesDiabetic Complications
SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
Diabetes Obes Metab.
Liu J, Li L, Li S, Wang Y, Qin X, Deng K, Liu Y, Zou K, Sun X
doi: 10.1111/dom.14075.
Diabetes - GeneralType 2 Diabetes
Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Front Endocrinol (Lausanne)
Zhang A, Luo X, Meng H, Kang J, Qin G, Chen Y, Zhang X
doi: 10.3389/fendo.2020.604250